RxDoctor Payments Data

David Ivanick, MD

Neurology · Seattle, WANPI 1629430137

Payments from drug & device makers

$3,416in general payments, 2019–2025

Across 32 payments — averaging $106.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Evolution Surgical, Inc$2K
  • Argenx US, Inc.$554
  • AstraZeneca$100
  • UCB, Inc.$97
  • Grifols USA, LLC$66
  • CSL Behring$58
  • plus $182 from 7 others

What the payments were for

  • Food & beverage$93727%
  • Education$2,47973%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,416 in reported general payments places this provider in the 75th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$110,647
Medicare patients
246
Services billed
3,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone155$2,198,333
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5030$444,997
RelyvrioSod Phenylbutyrat/Taurursodiol21$318,008
Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc19$291,454
Gamunex-CImmune Globul G/Gly/Iga Avg 4630$207,638
NuedextaDextromethorphan Hbr/Quinidine33$55,198
Riluzole103$33,869
Aimovig AutoinjectorErenumab-Aooe20$21,998
Mycophenolate Mofetil86$9,928
Emgality PenGalcanezumab-Gnlm13$8,593
Sumatriptan Succinate13$5,188
Pyridostigmine Bromide79$3,896
Gabapentin114$1,802
Pregabalin48$1,481
Carbidopa-Levodopa ErCarbidopa/Levodopa29$1,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$58$444,99730 claims
Argenx US, Inc.Vyvgart Hytrulo$554$291,45419 claims
Grifols USA, LLCGamunex-C$66$207,63830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 418 neurology providers in Washington.

Other neurology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →